In the fast-moving landscape of UK weight management, the debate has shifted. It is no longer just about which medication is more effective; it’s about which clinical workflow allows a pharmacy to scale safely, remain compliant with evolving GPhC standards, and protect its profit margins.

With the recent approval and rollout of the Wegovy 7.2mg dose and the continued dominance of Mounjaro (Tirzepatide), pharmacy owners are facing a strategic choice: how do you manage two high-demand, high-complexity services without doubling your admin?

Here is the 2026 breakdown of the Mounjaro vs. Wegovy clinical workflows and why a "unified" approach is the only way to win the High Street.

1. The Wegovy 7.2mg Evolution: Closing the Efficacy Gap

For a long time, Mounjaro held the "efficacy" crown. However, the introduction of the Wegovy 7.2mg dose (currently managed via a 3 x 2.4mg titration until the single-pen release later this year) has changed the conversation.

Many patients who were previously considering a switch to Mounjaro for better results are now opting to stay within the Semaglutide family to reach those higher maintenance levels.

The Deltera Edge: Our platform doesn't make you choose. Our unified Weight Management Service allows you to administer either Mounjaro and Wegovy under a single, streamlined clinical umbrella. Whether you are considering titrating a patient up to Wegovy 7.2mg or managing a Mounjaro maintenance dose, the system handles the specific titration schedules automatically, ensuring your pharmacists never have to "guess" the next step.

2. GPhC Governance: The "Visual Verification" Standard

The April 2026 GPhC report on weight management services sent a clear message: Remote "checkbox" consultations are no longer sufficient. Regulators are looking for robust verification of BMI and patient identity.

Currently, Deltera’s PGDs are designed for in-person consultations, which remain the "Gold Standard" for safety and GPhC compliance. However, we recognise the need for flexibility in a digital age.

Coming Summer 2026: Remote Consultations Redefined

We are excited to announce that our new PGD cycle, launching this summer, will introduce a Video-Consultation Workflow.

• Visual Verification: No more "self-reported" weights without oversight. The new workflow requires visual verification via a secure video link.

• Microsoft Outlook & Teams Integration: To make this seamless, Deltera is integrating directly with your Microsoft calendar. You’ll be able to schedule video consultations, send the invite to the patient, and conduct the clinical review—all within a single, audit-ready ecosystem.

3. The "PGD Wall" and the IP Bridge

Even the most advanced Mounjaro PGD Pharmacy setup has its limits. Clinical criteria for PGDs are necessarily rigid. If a patient presents with a BMI that has dipped into the maintenance zone, or if they have a nuanced medical history that technically excludes them from the PGD, most pharmacies have to turn that revenue away.

This is where the Deltera IP Bridge becomes your commercial safety net.

Instead of losing a long-term patient, your Independent Prescribers can take over the consultation. They can move the patient from a PGD-led supply to a Patient Specific Direction (PSD), using their clinical knowledge and assessing for risk, ensuring clinical continuity and 100% patient retention.

4. Operational Reality: Mounjaro vs. Wegovy

When deciding which service to "push" in your local marketing, consider the operational impact:

‍

Conclusion: Don't Choose a Drug, Choose a Workflow

In 2026, trying to manage individual PGDs for every different weight-loss medication is an administrative trap. The online giants win because they have scale; you win because you have integrated technology and local clinical authority.

By using a unified weight management service that is backed by clinical governance, you can offer both Mounjaro and Wegovy with total confidence.